HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

CPTS: Conceptus Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

CONCEPTUS INC (NASD)
CPTS 17.70 0.07 (0.40%) Vol.  196,304 16:00 ET

Day Low - High 17.41 - 17.74
52wk Low - High 10.26 - N/A
Avg Volume 320,729
Industry MED PRODUCTS
Market Cap 538.97 M
Div - Yield 0.00 - 0.00
PE (forward) 69.9
PEG Ratio 2.21
Current Year Est. .25
EPS Last Year 0.25
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 11/25/2009
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/23/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
CONCEPTUS INC CPTS PREMIUM
BIO-RAD LABS -A BIO PREMIUM
MICRUS CORP MEND PREMIUM
CAREFUSION CORP CFN PREMIUM
See all MED PRODUCTS Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.56
ABR (Last Week) 2.56
# of Recs in ABR 9
Average Target Price 22.67
Industry Rank by ABR 49 out of 217
Rank in Industry 61 out of 72
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate CPTS?
Buy
Sell
Find out what the Zacks Community
thinks of CPTS at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR CPTS
Zacks Equity Research: Report for CPTS
Nov 23, 2009
Zacks Blog: Zacks #1 Rank Additions for Thursday
Nov 19, 2009
Zacks Blog: Conceptus Enters Oversold Territory
Nov 11, 2009
Zacks Blog: Zacks Releases Four Powerful ''Buy'' Stocks: Conceptus, Inc., Nordstrom, Inc., Caterpillar, Inc. and Sabesp
Oct 28, 2009
Aggressive Growth: Conceptus, Inc.
Oct 28, 2009
More Zacks Commentary
NEWS
Conceptus to Participate at the Piper Jaffray Annual Healthcare Conference
Nov 23, 2009
Conceptus to Participate at the Piper Jaffray Annual Healthcare Conference
Nov 20, 2009
Conceptus Down 4.2% Since SmarTrend's Sell Recommendation
Nov 18, 2009
BiomedReports: News and FDA Updates for Advaxis (OTC:ADXS), AVANIR (NASDAQ:AVNR), Conceptus (Nasdaq:CPTS)
Nov 18, 2009
Conceptus(R) to Present at the Piper Jaffray 21st Annual Healthcare Conference
Nov 17, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate 0.22 -0.04 0.25 0.58
Number of Estimates 9 6 9 9
Low Estimates 0.20 -0.11 0.24 0.45
High Estimate 0.28 0.03 0.27 0.81
Year Ago EPS 0.17 -0.14 0.01 0.25
EPS Growth 30.72% 69.05% 2422.22% 128.19%

More Estimates

COMPANY DESCRIPTION
Conceptus, Inc. designs and develops minimally invasive devices for reproductive medical applications. Conceptus' focus is to develop its STOP non-surgical permanent contraception device for women. STOP is designed to be a less-invasive, safer, and less costly alternative to surgical sterilization, more commonly known as tubal ligation. The STOP device is designed to achieve contraception by elliciting a tissue response which occludes the fallopian tubes.

Full Company Report
FINANCIALS
EPS TTM .25
Sales 101.98
Net Income 6.27
Price/Earnings 70.52
Price/Book 10.3
Price/Cash Flow 116.29
Price/Sales 4.38


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research